Vol 13: Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.Report as inadecuate



 Vol 13: Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.


Vol 13: Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 13: Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment.
This article is from Molecular Cancer, volume 13.AbstractSolid cancer remains a major cause of death in the world. As limited treatment options are currently available to patients with solid cancer, novel preventive control and effective therapeutic approaches are considered to be reasonable and decisive measures to combat this disease. The plant-derived triterpenoids, commonly used for medicinal purposes in many Asian countries, poses various pharmacological properties. A large number of triterpenoids exhibit cytotoxicity against a variety of cancer cells, and cancer preventive, as well as anticancer efficacy in preclinical animal models. To improve antitumor activity, some synthetic triterpenoid derivatives have been synthesized, including cyano-3,12-dioxooleana-1,911- dien-28-oic CDDO, its methyl ester CDDO-Me, and imidazolide CDDO-Im derivatives. In this review, we will critically examine the current preclinical evidences of cancer preventive and therapeutic activity about one of the synthetic triterpenoids, CDDO-Me. Both in vitro and in vivo effects of this agent and related molecular mechanisms are presented.



Author: Wang, Yan-Yang; Zhe, Hong; Zhao, Ren

Source: https://archive.org/







Related documents